Revolution Medicines
Develops RAS(ON) therapeutics for KRAS-driven and broad RAS-driven solid tumors.
Something off on this page? Send us feedback.
Profile
Clinical-stage biotechnology focused on RAS(ON) inhibitors across KRAS-mutant and broader RAS-driven solid tumors, led by daraxonrasib and supported by parallel next-generation candidates.
Develops RAS(ON) oncology candidates for KRAS-mutant and broader RAS-driven solid tumors. The lead portfolio centerpiece is daraxonrasib (RMC-6236), supported by elironrasib and zoldonrasib as adjacent clinical-stage compounds.
RMC-6236 is positioned in pancreatic and lung oncology contexts, while other disclosed programs expand mutational coverage and combination options. Elironrasib and zoldonrasib add portfolio depth around the same RAS biology and same commercialization thesis.
Commercial operations are not yet established; execution depends on trial readouts, protocol discipline, and regulatory review outcomes in molecularly defined patient subsets.
Company facts
Key statistics
Year to date +163% · Average volume (30d) 1.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 28, 2026 | UBS | Reiterate | Buy | $175 | $265 |
| Aug 28, 2026 | Deutsche Bank | Upgrade | Buy | ||
| Aug 28, 2026 | Guggenheim | Reiterate | Buy | $240 | $275 |
| Aug 27, 2026 | RBC Capital | Reiterate | Outperform | $203 | $251 |
| Aug 27, 2026 | Raymond James | Reiterate | Strong Buy | $76 | $248 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$2.04 | −$3.06 | −50.0% | $1.8M | — | — | +0.26% |
| May 6, 2026Q1 FY26 | −$1.84 | −$2.29 | −24.5% | $2.4M | — | — | −5.67% |
| Feb 25, 2026Q4 FY25 | −$1.58 | −$1.86 | −17.7% | $3.7M | — | — | −1.06% |
| Nov 5, 2025Q3 FY25 | −$1.42 | −$1.61 | −13.4% | $1.7M | — | — | +3.44% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | −$4.7M | −$4.5M | $0 | |
| Operating income | −$240.8M | −$264.7M | −$315.3M | −$361.6M | −$445.2M | −$505.1M | |
| Net income | −$213.4M | −$247.8M | −$305.2M | −$364.9M | −$453.8M | −$644.4M | |
| Diluted EPS | −$1.13 | −$1.31 | −$1.61 | −$1.90 | −$2.29 | −$3.06 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $29.4M · FY22 $35.4M · FY23 $11.6M · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $3.94B · Total debt $641.9M · Total assets $4.32B · Shareholders' equity $2.61B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 212.60M · Float 190.10M · 89.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Farallon Capital Management LLC | 13.55M | 6.37% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 12.20M | 5.70% | 13G | Jul 29, 2026 |
| FMR LLC | 12.20M | 5.74% | 13F | Aug 13, 2026 |
| Baker Bros. Advisors LP | 11.44M | 5.30% | 13G | Aug 14, 2026 |
| Jupiter Topco LLC | 10.74M | 5.05% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Mark A. Goldsmith | director, officer: See Remarks | −86,000 | $209.20 |
| Aug 21, 2026 | Jeff Cislini | officer: General Counsel | −56,894 | $209.24 |
| Jun 29, 2026 | Sushil Patel | director | −5,580 | $187.99 |
| Jun 24, 2026 | Jack Anders | officer: Chief Financial Officer | −20,000 | $168.33 |
| Jun 16, 2026 | Stephen Michael Kelsey | officer: See Remarks | −4,175 | $156.12 |
Peers
- Amgen
Develops KRAS G12C colorectal program using sotorasib.
- Bristol-Myers Squibb
Markets adagrasib plus cetuximab for KRAS G12C-mutated CRC.
- Eli Lilly
Advancing olomorasib with KRAS-focused early clinical activity.
- Merck
Develops MK-1084 combinations for KRAS G12C first-line CRC.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Revolution Medicines | $208.55 | +0.23% | $44.19B | — | — | — | — |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Median | 33.1 | 17.8 | 5.8 | +7.7% |